Roomer R - Search Results

1

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Roomer R, et al. Hepatology. 2010 Oct;52(4):1225-31. doi: 10.1002/hep.23842. Hepatology. 2010. PMID: 20830784

2

Rationale and design of the virological response and ribavirin dosage (VIRID) study in hepatitis.

Bergmann JF, Slavenburg S, Roomer R, de Knegt RJ, Drenth JP. Bergmann JF, et al. Among authors: roomer r. Neth J Med. 2008 Jan;66(1):44-5. Neth J Med. 2008. PMID: 18219071 No abstract available.

3

Current clinical care compared with new Dutch guidelines for hepatitis C treatment.

Slavenburg S, Lamers MH, Roomer R, de Knegt RJ, van Oijen MG, Drenth JP. Slavenburg S, et al. Among authors: roomer r. Neth J Med. 2009 May;67(5):177-81. Neth J Med. 2009. PMID: 19581667 Free article.

4

Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.

Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Roomer R, et al. J Hepatol. 2010 Sep;53(3):455-9. doi: 10.1016/j.jhep.2010.04.013. Epub 2010 Jun 1. J Hepatol. 2010. PMID: 20561709

5

Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.

Roomer R, van Vuuren AJ, Schutten M, Heijens A, Janssen HL, de Knegt RJ. Roomer R, et al. Antivir Ther. 2011;16(5):771-4. doi: 10.3851/IMP1777. Antivir Ther. 2011. PMID: 21817199

6

Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.

Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans BL, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HL. Roomer R, et al. Antivir Ther. 2012;17(3):509-17. doi: 10.3851/IMP2016. Epub 2011 Dec 13. Antivir Ther. 2012. PMID: 22300892 Clinical Trial.

7

Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients.

Spaan M, Groothuismink ZM, Koning L, Roomer R, Janssen HL, De Knegt RJ, Boonstra A. Spaan M, et al. Among authors: roomer r. Antiviral Res. 2013 Jun;98(3):469-75. doi: 10.1016/j.antiviral.2013.04.003. Epub 2013 Apr 11. Antiviral Res. 2013. PMID: 23583759

8

Analysis of the transcriptome and immune function of monocytes during IFNα-based therapy in chronic HCV revealed induction of TLR7 responsiveness.

Hou J, Groothuismink ZM, Koning L, Roomer R, van IJcken WF, Kreefft K, Liu BS, Janssen HL, de Knegt RJ, Boonstra A. Hou J, et al. Among authors: roomer r. Antiviral Res. 2014 Sep;109:116-24. doi: 10.1016/j.antiviral.2014.06.020. Epub 2014 Jul 9. Antiviral Res. 2014. PMID: 25014880 Clinical Trial.

9

ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.

Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZM, Hansen BE, Veldt BJ, Janssen HL, Boonstra A, de Knegt RJ. Maan R, et al. Among authors: roomer r. PLoS One. 2015 Oct 6;10(10):e0139317. doi: 10.1371/journal.pone.0139317. eCollection 2015. PLoS One. 2015. PMID: 26441325 Free PMC article.

10

Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country.

Brakenhoff SM, Hoekstra R, Honkoop P, Roomer R, den Hollander JG, Bezemer G, de Knegt RJ, Sonneveld MJ, de Man RA. Brakenhoff SM, et al. Among authors: roomer r. Eur J Intern Med. 2023 Feb;108:68-73. doi: 10.1016/j.ejim.2022.11.024. Epub 2022 Nov 30. Eur J Intern Med. 2023. PMID: 36462966 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters